Recently, fibroblast growth factor 23 (FGF23) was identified as a novel risk factor not only in patients with end stage kidney disease [3] and advanced stages of CKD [4,5], but also in patients in the early stages of CKD and in the general population [6]. This evidence concerns the gene FGF23 and chronic kidney disease.